Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP4 | P49662 | 1/20 | 0.41 |
| ▸ | CASP5 | P51878 | 1/20 | 0.41 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104764 | 0.86 | CHKA (0.44) | CASP1CASP4CASP5CD274CHRM4 | |
| SCHEMBL13098873 | 0.81 | KDM4E (0.44) | CD274 | |
| SCHEMBL13098941 | 0.81 | KDM1A (0.39) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL6235992 | 0.81 | HDAC3 (0.54) | HDAC6CHRM4 | |
| SCHEMBL6132372 | 0.80 | HDAC3 (0.53) | HDAC6CHRM4 | |
| SCHEMBL13098926 | 0.80 | MAP4K4 (0.45) | HDAC6KDM1ACD274 | |
| SCHEMBL13098938 | 0.77 | ADRA1A (0.41) | HDAC6KDM1ACD274 | |
| SCHEMBL27793057 | 0.74 | BCL2L1 (0.45) | CASP1CASP4CASP5PRKAA2MTOR | |
| SCHEMBL27814329 | 0.72 | CASP1 (0.40) | CASP1CASP4CASP5 | |
| SCHEMBL3091661 | 0.71 | KDM4E (0.36) | CASP1CASP4CASP5TRPA1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101861330-A | Polypeptide compound | ASTELLAS PHARMA INC | 2010-10-13 | — | — | CN | disclosed |
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2204379-A1 | POLYPEPTIDE COMPOUND | Astellas Pharma Inc. (JP) | 2010-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | VIP, ANPEP, NPEPPS | CASP1 388/4885CASP4 339/4885CASP5 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.